Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World's First CGM System with No On-body Component

First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics' innovation roadmap, with potential launch in 2028

GlobeNewsWire • Oct 26, 2026

Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences

GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November: Stifel 2026 Healthcare Conference – November 10-12, 2026 (New York, NY) Management will participate in a fireside chat at 3:20 pm ET and host one-on-one meetings with investors on Tuesday, November 10th.

GlobeNewsWire • Oct 22, 2026

Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time

GERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2026 financial results after market close on Monday, November 9, 2026.

GlobeNewsWire • Oct 21, 2026

Senseonics: Eversense 365 Adoption Has To Earn The Valuation

Senseonics is rated Hold due to positive sales growth, margin improvement, and product differentiation, but with significant adoption and funding risks. SENS's Eversense 365 offers unique implantable CGM technology, but recurring revenue depends on repeat implantations and overcoming barriers like prescriber adoption and insurance approvals. Q2 2026 saw 117.8% sales growth and gross margin improvement to 59.1%, but high SG&A expenses, ongoing dilution, and negative free cash flow persist.

Seeking Alpha • Oct 8, 2026

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal

BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.

Zacks Investment Research • Sep 29, 2026

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world's first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ: BBNX), a pioneering leader in the development of advanced diabetes management solutions.

GlobeNewsWire • Sep 14, 2026

Senseonics To Participate in Upcoming Institutional Investor Conferences

GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences.

GlobeNewsWire • Sep 10, 2026

Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.

MarketBeat • Aug 7, 2026

Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript

Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates

Senseonics Holdings (SENS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.4 per share a year ago.

Zacks Investment Research • Aug 6, 2026